With more expensive drugs being introduced, some of them for highly prevalent conditions, and the pace of generic conversion slowing, policymakers may want to consider cost-effectiveness analyses for coverage decisions — but there would still be a budgetary problem.
No takes yet. Share an insight, caveat, or question.
Peter B. Bach (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: